Nimbus Therapeutics has raised $105 million to put its allosteric TYK2 inhibitor through a clutch of phase 2 clinical trials. The multifront midphase program is designed to determine whether the drug ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nimbus Therapeutics, a clinical-stage company that is working to design and develop breakthrough medicines through its powerful computational drug discovery engine, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback